HelsinkiUCH
Helsinki, Finland
NCT Number: NCT03300635
Fibromyalgia (FM) is a world widely common syndrome, characterized by widespread pain, often accompanied by general fatigue, soreness, and abnormal sensations (like "pins and needles"). The reasons and the mechanisms (pathogenesis) of FM are still poorly understood. Efficacious therapies cannot be developed without understanding the pathophysiological mechanisms of the disease or syndrome.
FM patients suffer from pain and sense of weakness and fatigue in the muscles, and often report difficulty in relaxing their muscles. So far, the studies on muscle activation in fibromyalgia (mostly using surface electromyography) have shown some unusual functioning, a kind of overuse, but the results have been somewhat contradictory.
FM symptoms share some features with small fibre neuropathy, which is a disease or abnormality of small nerve fibres with a diverse aetiology. Recently, several research groups have shown (studying both the electrical function of superficial nerves and nerve endings of skin samples) that up to 50% of the FM patients with severe symptoms have small fibre neuropathy: their small nerves do not function properly and small nerve fibre density in their skin is reduced. However, as this phenomenon is common but not a rule, it might be rather a consequence of some underlying mechanisms of the syndrome, creating even more symptoms.
The aim is to investigate whether there would exist metabolic changes in FM patients that would create pain and lead to functional changes and damage in small nerve fibres. The investigators also aim to explore the muscle function particularly in distressed situations and at rest. The hypothesis is that a towards-overuse-altered function would create unfavourable metabolic changes. Third, the aim is to investigate some psychological factors (such as tendency to get anxious or distressed) to find out, if there is any association between them and muscle function.
The FM patients as well as healthy control subjects will be recruited at Helsinki University Hospital Pain Clinic and from primary care at Vantaa Health Care Centre. The voluntary test subjects will attend
1. A muscle function examination of 30 minutes with electromyography using surface electrodes, including mentally distressing tasks and relaxing periods. At the same session, the subject will reply to some questionnaires regarding their symptoms and measuring some psychological factors. Actual pain level will be assessed. 2. A glucose tolerance test, with other blood samples 3. A bicycle ergometer exercise test of 20 - 30 minutes, with both physiological and chemical (blood samples) recordings. Actual pain level will be assessed as well.
At this stage, 40 patients and 20 healthy control subjects will be recruited.
Looking for future studies?
Notify Me18 year–65 year
Female
Interventional
Not applicable
Helsinki, Finland
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to day 3
the difference of value distribution in metabolics panel between groups
Time frame: Day 3 (at the end of Exercise test)
the difference of value distribution in metabolics panel between groups
Time frame: Day 2 ( at the end of Glucose test)
the difference of value distribution in metabolics panel between groups
Time frame: Day 1
sEMG signal amplitude
Time frame: Day 1
normalized signal amplitude (%sEMGmax)
Time frame: Day 1
time of sEMG signal amplitude < 0.5% sEMGmax
Time frame: Day 1 ( at the beginning of the recording during the Mental distress and relaxation test)
reported distress intensity (NRS)
Time frame: Day 1 (after the first relaxation phase of the Mental distress and relaxation test)
reported distress intensity (NRS)
Time frame: Day 1 (after the first mental stress phase of the Mental distress and relaxation test)
reported distress intensity (NRS)
Time frame: Day 1 (after the second relaxation phase of the Mental distress and relaxation test)
reported distress intensity (NRS)
Time frame: Day 1 (after the second mental stress phase of the Mental distress and relaxation test)
reported distress intensity (NRS)
Time frame: Day 1 ( after the third relaxation phase of the Mental distress and relaxation test)
reported distress intensity (NRS)
Time frame: Day 1 ( at the beginning of the recording during the Mental distress and relaxation test)
reported pain intensity (NRS)
Time frame: Day 1 ( after the first relaxation phase of the Mental distress and relaxation test)
reported pain intensity (NRS)
Time frame: Day 1 ( after the first mental stress phase of the Mental distress and relaxation test)
reported pain intensity (NRS)
Time frame: Day 1 (after the second relaxation phase of the Mental distress and relaxation test)
reported pain intensity (NRS)
Time frame: Day 1 (after the second mental stress phase of the Mental distress and relaxation test)
reported pain intensity (NRS)
Time frame: Day 1 (after the third relaxation phase of the Mental distress and relaxation test)
reported pain intensity (NRS)
Time frame: Day 1
variability of heart beat interval evaluated as root mean square successive difference (RMSSD)
Helsinki University Central Hospital
Other
Metaboliset Muutokset ja Lihastoiminta Fibromyalgiassa
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05998369
Abdominal Pain, Autonomic Nervous System Diseases
Palo Alto, California, United States
View Trial DetailsNCT06752590
Fibromyalgia, Muscular Diseases
Nagakute, Aichi-ken, Japan
View Trial DetailsNCT05237050
Chronic Pain, Fibromyalgia
Gap, Hautes Alpes, France
View Trial DetailsNCT07665411
Fibromyalgia, Muscular Diseases
Covilha, Castelo Branco District, Portugal
View Trial Details